Welcome to our dedicated page for Royalty Pharma Plc SEC filings (Ticker: RPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Royalty Pharma plc (Nasdaq: RPRX) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its royalty-based business model, capital structure and portfolio performance. As a company incorporated in England and Wales with Class A ordinary shares listed on The Nasdaq Stock Market LLC under the symbol RPRX, its SEC filings include annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, along with registration statements and indenture-related documents.
In its filings, Royalty Pharma explains how it acquires and manages royalty interests on biopharmaceutical products and defines key metrics such as Portfolio Receipts, royalty receipts, milestones and other contractual receipts. The company also discloses non-GAAP liquidity measures, including Adjusted EBITDA, ROIC Adjusted EBITDA, Portfolio Cash Flow and ROIE Portfolio Cash Flow, and reconciles these to net cash provided by operating activities. Debt-related filings describe senior unsecured notes issued under an indenture among Royalty Pharma plc, Royalty Pharma Holdings Ltd, Royalty Pharma Manager, LLC and Wilmington Trust, National Association, as trustee, including coupon rates, maturities, guarantees and covenant terms.
Form 8-K current reports highlight material events such as quarterly earnings releases, debt offerings, changes in directors and other significant corporate developments. These filings can be used to track Royalty Pharma’s capital deployment into new royalty transactions, updates to its share repurchase program, dividend decisions and other actions affecting shareholders.
On Stock Titan’s SEC filings page for RPRX, users can access Royalty Pharma’s latest 10-K, 10-Q and 8-K filings as they are posted to EDGAR. AI-powered summaries help explain complex sections, such as the description of Portfolio Receipts, non-GAAP liquidity measures, and indenture provisions for senior notes, allowing readers to quickly understand the implications of lengthy documents. The page also surfaces Form 4 insider transaction reports, so users can review trading activity by directors and officers alongside the company’s broader disclosure record.
Royalty Pharma plc executive Marshall Urist reported an automatic share sale under a pre-arranged trading plan. On January 30, 2026, an entity listed as Sandy Lamm LLC sold 20,000 Class A Ordinary Shares at a weighted average price of $41.0905 per share under a Rule 10b5-1 plan adopted on September 16, 2025.
After this sale, accounts associated with Urist continued to hold 19,020 Class A Ordinary Shares indirectly through an IRA and 7,398 Class A Ordinary Shares directly. The filing also notes additional exchangeable partnership and Class E ordinary share interests that could convert into Class A Ordinary Shares, subject to vesting conditions.
Royalty Pharma plc executive Marshall Urist, EVP of Research & Investments, reported a planned sale of Class A Ordinary Shares through an affiliated entity. On January 23, 2026, 20,000 Class A Ordinary Shares were sold by Sandy Lamm LLC, an entity associated with Urist, at a weighted average price of $40.2555 per share under a pre-established Rule 10b5-1 trading plan adopted on September 16, 2025.
Following this transaction, the filing shows indirect ownership of 20,000 shares through Sandy Lamm LLC, 19,020 shares held indirectly via an IRA, and 7,398 shares held directly. The filing also notes additional exchangeable interests and Class E Ordinary Shares in affiliated Royalty Pharma entities that can convert into Royalty Pharma plc Class A Ordinary Shares, with some of those Class E shares subject to vesting conditions.
Royalty Pharma plc EVP & CFO Terrance P. Coyne reported automatic sales of Class A Ordinary Shares through entities associated with him. On January 20, 2026, TPC RP 2021, LLC sold 65,832 Class A shares at a weighted average price of $39.3484 per share, leaving 394,996 shares held indirectly by that LLC. On the same date, TPC RP EPA1 LLC sold 3,750 Class A shares at a weighted average price of $39.3484, with 36,010 shares remaining held indirectly by that LLC.
All reported sales were made under a Rule 10b5-1 trading plan adopted by Coyne on August 8, 2025, meaning they were pre-arranged. In addition, Coyne reports indirect holdings of Class A shares through a spouse’s IRA, his own IRA, and shares held by his spouse, as well as limited partnership and Class E Ordinary Share interests that are exchangeable for additional Class A Ordinary Shares, with some of those interests subject to vesting conditions.
Royalty Pharma EVP Marshall Urist, through Sandy Lamm LLC, sold 20,000 Class A Ordinary Shares of Royalty Pharma plc on January 16, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on September 16, 2025. The shares were sold at a weighted average price of $39.5173 in multiple trades between $39.37 and $39.76 per share. Following the sale, Sandy Lamm LLC held 40,000 shares, an IRA associated with the reporting person held 19,020 shares, and 7,398 shares were held directly. In addition, the reporting person and family vehicles hold limited partnership and holding company interests exchangeable into 2,474,120 and 1,356,528 Class A Ordinary Shares, with certain Class E shares subject to vesting conditions.
A holder of the issuer’s common stock has filed a Form 144 notice to sell 69,582 shares of common stock through Goldman Sachs & Co. LLC, with an aggregate market value of $2,719,960.38. The filing notes that there were 427,247,489 shares of this class outstanding and that the approximate sale date is January 20, 2026 on the NASD.
The shares to be sold were originally acquired from the issuer in 2020, including 65,832 shares in a private transaction on June 16, 2020 and 3,750 shares as compensation performance awards on February 12, 2020. The notice also lists prior sales over the past three months by entities such as TPC RP 2021 LLC and TPC RP EPA1 LLC, including blocks of 32,916 shares of common stock on various dates, with single transactions generating gross proceeds such as $1,277,555.54.
Royalty Pharma plc reported an insider transaction involving an entity affiliated with its EVP, Research & Investments, Marshall Urist. On January 9, 2026, Sandy Lamm LLC, an entity associated with Urist, sold 20,000 Class A Ordinary Shares at a weighted average price of $40.7817 per share pursuant to a Rule 10b5-1 trading plan adopted on September 16, 2025. After this sale, 60,000 Class A Ordinary Shares were held indirectly through Sandy Lamm LLC, 19,020 shares were held indirectly through an IRA, and 7,398 shares were held directly.
Royalty Pharma has a planned Rule 144 sale of 495860 shares of common stock through Goldman Sachs & Co. LLC, with an aggregate market value of 20523645.4 and 427247489 shares outstanding. The shares are expected to be sold on or about 01/07/2026 on NASD. They were originally acquired from the issuer in a private transaction on 06/16/2020, with 495860 shares received on that date.
Over the past 3 months, the person for whose account the securities are to be sold and related entities have already sold multiple blocks of common stock, including 3000 shares on 11/19/2025 for gross proceeds of 113364 and 110000 shares on 12/03/2025 for 4375008. Additional sales by entities such as GWL 2014 G LLC, GWL 2020 G LLC, GWL 2023 G HoldCo LLC, and GWL 2021 G LLC are also listed, reflecting an ongoing disposition program.
Royalty Pharma plc’s EVP & CFO Terrance P. Coyne reported indirect sales of Class A Ordinary Shares through entities associated with him. On January 2, 2026, TPC RP 2021, LLC sold 65,832 Class A shares and TPC RP EPA1 LLC sold 3,750 Class A shares, both at a weighted average price of $38.4157 per share, under a Rule 10b5-1 trading plan adopted on August 8, 2025.
After these trades, TPC RP 2021, LLC held 460,828 Class A shares and TPC RP EPA1 LLC held 39,760 Class A shares, reported as indirect holdings for Coyne. Additional indirect holdings include shares held through the reporting person’s and spouse’s IRAs and by the spouse, as well as partnership and Royalty Pharma Holdings Ltd interests exchangeable into 6,448,180 and 1,807,277 Class A shares, respectively, with the latter subject to vesting conditions.
Royalty Pharma plc executive Marshall Urist, EVP of Research & Investments, reported selling 20,000 Class A Ordinary Shares on December 16, 2025. The sale, coded as "S," was executed at a weighted average price of $38.321 per share, with individual trades ranging from $38.24 to $38.40. All transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 16, 2025.
Following this activity, Urist reports beneficial ownership of 140,000 Class A shares indirectly through Sandy Lamm LLC, 19,020 shares indirectly through an IRA, and 7,398 shares held directly. In addition, Urist and related family vehicles hold limited partnership interests exchangeable into 2,474,120 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into a further 1,356,528 Class A Ordinary Shares, with the Class E shares subject to vesting conditions.
Royalty Pharma plc executive vice president and chief financial officer Terrance P. Coyne reported selling Class A ordinary shares of Royalty Pharma plc on 12/15/2025 under a pre-arranged Rule 10b5-1 trading plan. The filing shows a sale of 65,832 Class A shares at a weighted average price of $38.3601 per share, with individual trades occurring between $38.10 and $38.48 per share.
After these transactions, Coyne continues to report indirect beneficial ownership of 526,660 Class A shares through TPC RP 2021, LLC and 43,510 Class A shares through TPC RP EPA1 LLC, along with additional holdings in IRA and spouse accounts. The remarks also state that entities controlled by him hold interests exchangeable into 6,448,180 Class A shares and Class E shares exchangeable into 1,807,277 Class A shares, with the Class E shares subject to vesting conditions.